Search for: "chimeric antigen receptor" - 8 articles found

Photo

Cancer research

'Gene ferry' improves immune therapies

Genetically enhancing a patient's immune cells by adding therapeutic genes to them outside the body is regarded as a promising new treatment approach in oncology. However, the production of these therapeutic cells using viruses is not only expensive but time-consuming. Researchers at the German Cancer Research Center (DKFZ) have developed an innovative non-viral vector that can efficiently…

Photo

New transfection approach

Immunotherapy: The 'FedEx and UPS equivalent of DNA delivery'

Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body. Chimeric Antigen Receptor (CAR)-T cell therapy, for instance, is a…

Photo

Therapeutic progress

Cancer: riding the wave of innovation

In haematology and medical oncology, there is always something new. However, the increasing stratification of cancer therapies presents an enormous challenge for clinical research. Tumour cells – those altered genetically by mutation and thus ought to be recognised by the immune system and destroyed – manage to apply diverse molecular tricks to avoid attack by the immune system. Thus, they…

Photo

Marine bioluminescence

Deep sea creatures light the way to develop cancer-fighting therapies

A team of scientists at the Keck School of Medicine of USC is looking to some deep sea dwellers to create a better way to develop cancer-fighting therapies. Harnessing the power of the enzymes that give these marine animals the ability to glow, the team created a test that makes it easy for researchers to see whether a therapy is having its intended effect — killing cancer cells. The results of…

Photo

Antiviral design

CAR-T gene therapy could provide long-term HIV protection

Through gene therapy, researchers engineered blood-forming stem cells (hematopoietic stem/progenitor cells, or HSPCs) to carry chimeric antigen receptor (CAR) genes to make cells that can detect and destroy HIV-infected cells. These engineered cells not only destroyed the infected cells, they persisted for more than two years, suggesting the potential to create long-term immunity from the virus…

Photo

Immunotherapy

apceth and University of Cologne to Join Forces

apceth announced a broad partnership with the Center for Molecular Medicine Cologne (CMMC), University of Cologne, to combine technologies and expertise, on the development of immunotherapies for solid tumors and haematological malignancies. The collaboration will start immediately and is based on combinations of Chimeric Antigen Receptor (CAR) T cells, developed at the laboratory of Prof Hinrich…

Subscribe to Newsletter